NEOG

NeogenD

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

20%

Probability

Target price

$12.50

Analysis reference price unavailable

Analysis 2026-07-30 · RankAlpha Sentiment Codex

Most likely

Base case

55%

Probability

Target price

$10.50

Analysis reference price unavailable

Analysis 2026-07-30 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$7.50

Analysis reference price unavailable

Analysis 2026-07-30 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-30

AI commentary

The earnings follow-up is mixed-positive rather than decisively bullish: the company reported strong Food Safety core growth, positive free cash flow, and a better-than-consensus EPS figure, while revenue was flat and GAAP EPS was negative. MarketBeat showed a 7.6% extended-hours gain, but no post-print analyst revisions were identified. The scheduler labels the earnings date as July 27, while the company and SEC filing confirm July 30; confidence remains moderate. [#SEC-8K-2026-07-30](https://www.sec.gov/Archives/edgar/data/711377/000119312526324860/neog-ex99_1.htm)

RankAlpha Sentiment Codex - 2026-07-30

Open post-earnings memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Impact

tentative

Confidence

AI events

2026-07-30eventQ4 FY26 earnings beat with mixed operating profileMedium impact

The SEC-filed release reported Q4 revenue of $225.3 million, 4.3% core growth, Food Safety core growth of 5.8%, adjusted EPS of $0.09, adjusted EBITDA margin of 20.2%, and positive free cash flow. MarketBeat reported EPS of $0.08 versus $0.05 consensus and a 7.6% extended-hours gain. Evidence is mixed because reported revenue was essentially flat and GAAP EPS was negative. [#SEC-8K-2026-07-30](https://www.sec.gov/Archives/edgar/data/711377/000119312526324860/neog-ex99_1.htm)

2026-10-28eventAnimal Safety supply recovery validationMedium impact

Animal Safety revenue grew 7% sequentially in Q4 as most supplier challenges were resolved, although year-over-year revenue still declined 8.2%. Sustained recovery would support the turnaround case; renewed supply disruption would weaken it. [#SEC-8K-2026-07-30](https://www.sec.gov/Archives/edgar/data/711377/000119312526324860/neog-ex99_1.htm)

2027-07-30catalystPetrifilm manufacturing transitionHigh impact

Neogen expects its first fully validated single-kit SKU by the end of August 2026 and plans to begin a multi-quarter manufacturing transition in November 2026. Execution could improve supply availability and future growth, but validation and ramp risks remain. [#SEC-8K-2026-07-30](https://www.sec.gov/Archives/edgar/data/711377/000119312526324860/neog-ex99_1.htm)

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-30 • Updated nightlySource: Internal modelMethodology